Table 1.
Comparison of demographic and clinical characteristics of the patients enrolled in the study before and after propensity-score matching.
| Variables | Before PSM | After PSM | ||||
|---|---|---|---|---|---|---|
| Sintilimab group (n = 98) |
Pembrolizumab group (n = 127) |
p-value | Sintilimab group (n = 63) |
Pembrolizumab group (n = 63) |
p-value | |
| Gender | 0.093 | 0.607 | ||||
| Male, n (%) | 83 (84.7%) | 96 (75.6%) | 53 (83.1%) | 50 (79.4%) | ||
| Female, n (%) | 15 (15.3%) | 31 (24.4%) | 10 (15.9%) | 13 (20.6%) | ||
| Age, | 0.865 | 0.613 | ||||
| mean ± SD (years) | 61.1 ± 9.8 | 60.9 ± 10.2 | 60.6 ± 9.9 | 61.9 ± 10.7 | ||
| ≤60, n (%) | 44 (44.9%) | 53 (41.7%) | 30 (47.6%) | 25 (39.7%) | ||
| >60, n (%) | 54 (55.1%) | 74 (58.3%) | 33 (52.4%) | 38 (60.3%) | ||
| PS score, n (%) | 0.079 | 0.561 | ||||
| 0 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||
| 1 | 53 (54.1%) | 69 (54.3%) | 33 (52.4%) | 30 (47.6%) | ||
| 2 | 19 (19.4%) | 17 (13.4%) | 28 (44.4%) | 30 (47.6%) | ||
| 3 | 26 (26.5%) | 41 (32.3%) | 2 (3.1%) | 3 (4.8%) | ||
| Histological type, n (%) | 0.754 | 0.690 | ||||
| Adenocarcinoma | 66 (67.3%) | 83 (65.4%) | 39 (61.9%) | 42 (66.7%) | ||
| Squamous carcinoma | 32 (32.7%) | 44 (36.6%) | 24 (38.1%) | 21 (33.3%) | ||
| TNM stage, n (%) | 0.325 | 0.826 | ||||
| IIIA | 6 (6.1%) | 6 (4.7%) | 4 (6.3%) | 6 (9.5%) | ||
| IIIB | 16 (16.3%) | 11 (8.7%) | 10 (15.9%) | 7 (11.1%) | ||
| IIIC | 1 (1.0%) | 7 (5.5%) | 1 (1.6%) | 4 (6.3%) | ||
| IV | 75 (76.5) | 103 (81.1%) | 48 (76.2%) | 46 (73.0%) | ||
| Bain metastases, n (%) | 0.121 | 0.607 | ||||
| Yes | 16 (16.3%) | 12 (9.4%) | 7 (11.1%) | 10 (15.9%) | ||
| No | 82 (83.7%) | 115 (90.6%) | 56 (88.9%) | 53 (84.1%) | ||
| Lines, n (%) | 0.726 | 0.804 | ||||
| First line | 51 (52.0%) | 69 (54.3%) | 34 (54.0%) | 36 (57.1%) | ||
| Second line | 19 (19.4%) | 17 (13.4%) | 14 (22.2%) | 7 (11.1%) | ||
| Third or more line | 28 (28.6%) | 41 (32.3%) | 15 (23.8%) | 20 (31.7%) | ||
| PD-L1 level, n (%) | 0.000 | 0.435 | ||||
| Positive | 81 (82.7%) | 53 (41.7%) | 13 (20.6%) | 24 (38.1%) | ||
| Negative | 17 (17.3%) | 74 (58.3%) | 50 (79.4%) | 39 (61.9%) | ||
| Comorbidities, n (%) | 0.355 | 0.557 | ||||
| Yes | 41 (41.8%) | 61 (48.0%) | 28 (44.4%) | 32 (50.8%) | ||
| No | 57 (58.2%) | 66 (52.0%) | 35 (55.6%) | 31 (49.2%) | ||
| Smoking status, n (%) | 0.297 | 0.597 | ||||
| Never | 43 (43.9%) | 47 (37.0%) | 22 (34.9%) | 26 (41.3%) | ||
| Former or current | 55 (56.1%) | 80 (63.0%) | 41 (65.1%) | 37 (58.7%) | ||
| Regimen, n (%) | 0.079 | 0.261 | ||||
| with radiotherapy | 44 (44.9%) | 72 (56.7%) | 29 (46.0%) | 31 (49.2%) | ||
| without radiotherapy | 54 (55.1%) | 55 (43.3%) | 34 (54.0%) | 32 (50.8%) | ||